Evidence map›Paper›PMID 36321403›Full record

ArticleHepatology communications2022

NPRL2 down-regulation facilitates the growth of hepatocellular carcinoma via the mTOR pathway and autophagy suppression.

Ya-Chin Wang, Ming-Chao Tsai, Yaw-Sen Chen, Pei-Min Hsieh, Chao-Ming Hung, Hung-Yu Lin, Yao-Chun Hsu, Jen-Hao Yeh, Pojen Hsiao, Yu-Cheih Su and 10 more

Open access · goldAbstract read
In one paragraph

Article in Hepatology communications, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 16 citations in OpenAlex.

  1. Protective effects ofHistology and histopathology · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. eLife · 2025
    Article
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 8 institutions in 1 country.

Ya-Chin WangDivision of Gastroenterology and Hepatology, E-Da Dachang Hospital, I-Shou University, Kaohsiung, Taiwan.
Ming-Chao TsaiDivision of Hepato-Gastroenterology, Department of Medicine, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung, Taiwan.
Yaw-Sen ChenSchool of Medicine, College of Medicine, I-Shou University, Kaohsiung, Taiwan.
Pei-Min HsiehSchool of Medicine, College of Medicine, I-Shou University, Kaohsiung, Taiwan.
Chao-Ming HungSchool of Medicine, College of Medicine, I-Shou University, Kaohsiung, Taiwan.
Hung-Yu LinSchool of Medicine, College of Medicine, I-Shou University, Kaohsiung, Taiwan.
Yao-Chun HsuSchool of Medicine, College of Medicine, I-Shou University, Kaohsiung, Taiwan.
Jen-Hao YehDivision of Gastroenterology and Hepatology, E-Da Dachang Hospital, I-Shou University, Kaohsiung, Taiwan.
Pojen HsiaoDivision of Gastroenterology and Hepatology, E-Da Dachang Hospital, I-Shou University, Kaohsiung, Taiwan.
Yu-Cheih SuSchool of Medicine, College of Medicine, I-Shou University, Kaohsiung, Taiwan.
Ching-Hou MaDepartment of Orthopedic Surgery, E-Da Hospital, I-Shou University, Kaohsiung, Taiwan.
Chih-Yuan LeeDepartment of Surgery, National Taiwan University Hospital, Taipei, Taiwan.
Chih-Che LinDepartment of Surgery, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan.
Chih-Wen ShuSchool of Medicine, College of Medicine, I-Shou University, Kaohsiung, Taiwan.
Yu-Chan LiDivision of Gastroenterology and Hepatology, E-Da Dachang Hospital, I-Shou University, Kaohsiung, Taiwan.
Mei-Hsing TsaiSchool of Medicine, College of Medicine, I-Shou University, Kaohsiung, Taiwan.
James Yu LinDivision of Gastroenterology and Hepatology, E-Da Dachang Hospital, I-Shou University, Kaohsiung, Taiwan.
Wei-Hao PengSchool of Medicine, College of Medicine, I-Shou University, Kaohsiung, Taiwan.ORCID 0000-0002-7524-1218
Ming-Lung YuHepatobiliary Section, Department of Internal Medicine, Hepatitis Center, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan.ORCID 0000-0001-8145-1900
Chih-Wen LinDivision of Gastroenterology and Hepatology, E-Da Dachang Hospital, I-Shou University, Kaohsiung, Taiwan.ORCID 0000-0003-2344-5056
E-Da Hospital · TWI-Shou University · TWChina Medical University · TWChang Gung University · TWKaohsiung Medical University · TWKaohsiung Chang Gung Memorial Hospital · TWNational Taiwan University Hospital · TWNational University of Kaohsiung · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatocellular carcinoma (HCC) is a highly invasive malignancy. Recently, GATOR1 (Gap Activity TOward Rags 1) complexes have been shown to play an important role in regulating tumor growth. NPRL2 is a critical component of the GATOR1 complex. Therefore, this study used NPRL2 knockdown to investigate how GATORC1 regulates the prognosis and development of HCC via the mammalian target of rapamycin (mTOR) and autophagy signaling pathways. We established HepG2 cells with NPRL2 knockdown using small interfering RNA (siRNA) and short hairpin RNA (shRNA) systems. The siRNA-mediated and shRNA-mediated NPRL2 down-regulation significantly reduced the expression of NPRL2 and two other GATPOR1 complex components, NPRL3 and DEPDC5, in HepG2 cells; furthermore, the efficient down-regulation of NPRL2 protein expression by both the shRNA and siRNA systems enhanced the proliferation, migration, and colony formation in vitro. Additionally, the NPRL2 down-regulation significantly increased HCC growth in the subcutaneous and orthotopic xenograft mouse models. The NPRL2 down-regulation increased the Rag GTPases and mTOR activation and inhibited autophagy in vitro and in vivo. Moreover, the NPRL2 level in the tumors was significantly associated with mortality, recurrence, the serum alpha fetoprotein level, the tumor size, the American Joint Committee on Cancer stage, and the Barcelona Clinic Liver Cancer stage. Low NPRL2, NPRL3, DEPDC5, and LC3, and high p62 and mTOR protein expression in the tumors was significantly associated with disease-free survival and overall survival in 300 patients with HCC after surgical resection. Conclusion: The efficient down-regulation of NPRL2 significantly increased HCC proliferation, migration, and colony formation in vitro, and increased HCC growth in vivo. Low NPRL2 protein expression in the tumors was closely correlated with poorer clinical outcomes in patients with HCC. These results provide a mechanistic understanding of HCC and aid the development of treatments for HCC.

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsAnimalsAutophagyDown-RegulationGTPase-Activating ProteinsHumansMammalsMiceRNA, Small InterferingTOR Serine-Threonine KinasesTumor Suppressor ProteinsGTPase-Activating ProteinsMTOR protein, humanNPRL2 protein, humanNPRL3 protein, humanRNA, Small InterferingTOR Serine-Threonine KinasesTumor Suppressor Proteins

Identifiers

PMID36321403
PMCPMC9701468
OpenAlexW4307972793

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.